• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

    3/11/25 8:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRBP alert in real time by email
    • CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study
    • Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancer
    • CRB 913 SAD/MAD obesity study expected to start in March 2025
    • $149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027

    NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024.

    "During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs (CRB-701 and CRB-601) have been advancing in the clinic and our obesity program (CRB-913) is on schedule for first in human dosing later this month. We were encouraged by the data for CRB-701 from our study in Western patients that has demonstrated a promising safety profile and encouraging evidence of efficacy in multiple advanced tumor types. We look forward to generating informative clinical data from all three of our programs in the 2nd half of this year" said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

    Key Corporate and Program Updates

     

     CRB-701 for the treatment of solid tumors, is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using monomethyl auristatin E (MMAE) as the payload.
      
    • Western study dose escalation data for CRB-701 Phase 1 was presented as a poster presentation at ASCO GU 2025. The Phase 1/2 study (NCT06265727) is being conducted by Corbus in the U.S. and Europe.
       Study Highlights:
        
    • Safety, tolerability and PK comparable to SYS6002 Ph1 China data presented at ASCO 2024 by our partner CSPC. No dose-limiting toxicities were observed in either study.
        
    • Low levels of peripheral neuropathy and skin toxicity were observed in both studies.
        
    • Clinical responses were seen in urothelial (mUC) and cervical cancer participants in both studies.
        
    • First-time targeting of head and neck squamous cell carcinoma (HNSCC) in the Western study yielded multiple responses.
      
    • Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tumors. More cohorts may be added to address additional tumor types in the expansion phase. The Company expects to complete dose optimization and establish a recommended Phase 2 dose ("RP2D") under Project Optimus in the fourth quarter of 2025.
      
    • In December 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer.
         
     CRB-913 is a second-generation, highly peripherally restricted CB1 receptor inverse agonist drug designed to treat obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss. CRB-913 will be the most peripherally restricted CB1 inverse agonist to be explored in a clinical setting to date.
      
    • Presented pre-clinical data at Obesity Week 2024 demonstrating CRB-913 is markedly more peripherally restricted than either monlunabant or rimonabant. CRB-913 has a brain to plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant.
      
    • The Company expects to dose the first participant in the Phase 1 SAD/MAD study in March 2025. We expect to commence a Phase 1 dose-range finding study in the fourth quarter of 2025.
         
     CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody for the treatment of solid tumors.
      
    • The first patient was dosed in December 2024 in a dose escalation portion of a Phase 1 study that is taking place in the U.S. and Europe. We expect to complete dose escalation in the fourth quarter of 2025.
         

    Financial Results for the Quarter and Year Ended December 31, 2024:

    The Company reported a net loss of approximately $9.5 million, or a net loss per diluted share of $0.78 per share, for the three months ended December 31, 2024, compared to a net loss of approximately $8.0 million, or a net loss per diluted share of $1.81, for the same period in 2023. For the year-ended December 31, 2024, the Company reported a net loss of approximately $40.2 million, or a net loss per diluted share of $3.68, compared to a net loss of $44.6 million, or a net loss per diluted share of $10.31, for the same period in 2023.

    Operating expenses for Q4 2024 increased by $2.5 million to approximately $12.6 million for the three months ended December 31, 2024, compared to $10.1 million in the comparable period in the prior year. The $2.5 million increase was primarily attributable to product development and stock-based compensation costs.

    The Company had $149.1 million in cash, cash equivalents and investments on hand at December 31, 2024, which is expected to fund operations through Q3 2027, based on current planned expenditures.

    About Corbus

    Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and are committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

    Forward-Looking Statements

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

    INVESTOR CONTACT:

    Sean Moran

    Chief Financial Officer

    Corbus Pharmaceuticals

    [email protected]

    Bruce Mackle

    Managing Director

    LifeSci Advisors, LLC

    [email protected]

    ---tables to follow---

          
    Corbus Pharmaceuticals Holdings, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (in thousands, except share and per share amounts)

          
     Unaudited

    For the Three Months

    Ended December 31,
      For the Year Ended

    December 31,
     
     2024  2023  2024  2023 
    Operating expenses:           
    Research and development$8,787  $6,980  $32,222  $31,168 
    General and administrative 3,818   3,124   16,499   13,910 
    Total operating expenses 12,605   10,104   48,721   45,078 
    Operating loss (12,605)  (10,104)  (48,721)  (45,078)
    Other income (expense), net:           
    Interest and investment income, net 1,782   350   6,311   1,636 
    Interest expense —   (929)  (1,872)  (3,858)
    Other income, net 1,293   2,661   4,073   2,696 
    Total other income, net 3,075   2,082   8,512   474 
    Net loss$(9,530) $(8,022) $(40,209) $(44,604)
    Net loss per share, basic and diluted$(0.78) $(1.81) $(3.68) $(10.31)
    Weighted average number of common shares outstanding, basic and diluted 12,179,482   4,423,683   10,915,413   4,327,568 
                
    Comprehensive loss:           
    Net loss$(9,530) $(8,022) $(40,209) $(44,604)
    Other comprehensive income:           
    Change in unrealized gain on marketable debt securities (172)  6   36   125 
    Total other comprehensive income (172)  6   36   125 
    Total comprehensive loss$(9,702) $(8,016) $(40,173) $(44,479)
                    



    Corbus Pharmaceuticals Holdings, Inc.

    Consolidated Balance Sheets

    (in thousands, except share and per share amounts)

          
     December 31, 2024  December 31, 2023 
          
    ASSETS     
    Current assets:     
    Cash and cash equivalents$17,198  $13,724 
    Investments 131,864   7,182 
    Restricted cash 285   192 
    Prepaid expenses and other current assets 3,629   2,448 
    Total current assets 152,976   23,546 
    Restricted cash 385   478 
    Property and equipment, net 385   973 
    Operating lease right-of-use assets 2,133   3,063 
    Other assets —   212 
    Total assets$155,879  $28,272 
    LIABILITIES AND STOCKHOLDERS' EQUITY     
    Current liabilities:     
    Notes payable$—  $301 
    Accounts payable 4,786   3,179 
    Accrued expenses 5,426   11,030 
    Derivative liability —   39 
    Operating lease liabilities, current 1,606   1,437 
    Loan payable —   15,908 
    Total current liabilities 11,818   31,894 
    Other long-term liabilities —   44 
    Operating lease liabilities, noncurrent 1,633   3,239 
    Total liabilities 13,451   35,177 
    Stockholders' equity     
    Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares

    issued and outstanding at December 31, 2024 and December 31, 2023.
     —   — 
    Common stock, $0.0001 par value; 300,000,000 shares authorized,

    12,179,482 and 4,423,683 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively
     1   — 
    Additional paid-in capital 619,285   429,780 
    Accumulated deficit (476,893)  (436,684)
    Accumulated other comprehensive gain (loss) 35   (1)
    Total stockholders' equity (deficit) 142,428   (6,905)
    Total liabilities and stockholders' equity$155,879  $28,272 
            


    Primary Logo

    Get the next $CRBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRBP

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    3/6/2024$4.00 → $46.00Hold → Buy
    Jefferies
    More analyst ratings

    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/11/24 5:34:06 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/6/24 4:00:46 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hodgson Ian claimed ownership of 25,977 shares (SEC Form 3)

      3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/18/25 4:45:04 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Smethurst Dominic sold $43,330 worth of shares (6,393 units at $6.78), decreasing direct ownership by 8% to 70,807 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/7/25 4:30:08 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Sean F. sold $24,446 worth of shares (2,792 units at $8.76), decreasing direct ownership by 4% to 73,313 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/18/25 5:40:54 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 7:48:14 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 6:41:20 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:05:29 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CRBP
    SEC Filings

    See more

    $CRBP
    Leadership Updates

    Live Leadership Updates

    See more
    • Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY. 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: May 21, 2025Time: 8:30 a.m. ETWebcast: Click here About CorbusCorbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people def

      5/8/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumors NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. "During the first quarter of 2025, we continu

      5/6/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

      CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the

      3/28/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

      10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 4:21:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 8:30:09 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.

      DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      4/1/25 4:36:19 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

      NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

      8/20/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

      NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

      2/28/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

      NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o

      3/6/23 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Corbus Pharma

      William Blair initiated coverage of Corbus Pharma with a rating of Outperform

      2/28/25 7:22:12 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corbus Pharma

      Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

      12/2/24 9:55:40 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Corbus Pharma with a new price target

      Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00

      7/30/24 6:19:42 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care